Synthetic Biology for Combating Leishmaniasis

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2024 Feb 16

PMID 38362504

Authors

Shweta Khandibharad

Shailza Singh

Affiliations

Soon will be listed here.

Abstract

Leishmaniasis is a neglected tropical disease caused by protozoan parasites of the genus. Despite the efforts to control and treat the disease, it still remains a major public health problem in many countries. Synthetic biology is a rapidly evolving interdisciplinary field that combines biology, engineering, and computer science to design and construct novel biological systems. In recent years, synthetic biology approaches have shown great promise for developing new and effective strategies to combat leishmaniasis. In this perspective, we summarize the recent advances in the use of synthetic biology for the development of vaccines, diagnostic tools, and novel therapeutics for leishmaniasis.

Citing Articles

Pharmacokinetics, Dose-Proportionality, and Tolerability of Intravenous Tanespimycin (17-AAG) in Single and Multiple Doses in Dogs: A Potential Novel Treatment for Canine Visceral Leishmaniasis.

Ferrante M, Leite B, Fontes L, Santos Moreira A, Nascimento de Almeida E, Brodskyn C Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931434 PMC: 11206245. DOI: 10.3390/ph17060767.

References

Frezard F, Aguiar M, Ferreira L, Ramos G, Santos T, Borges G . Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations. Pharmaceutics. 2023; 15(1). PMC: 9864876. DOI: 10.3390/pharmaceutics15010099. View

Vacas A, Sugden C, Velasco-Rodriguez O, Algarabel-Olona M, Pena-Guerrero J, Larrea E . Construction of Two mCherry Plasmids (pXG-mCherry) for Transgenic : Valuable Tools for Future Molecular Analysis. J Parasitol Res. 2017; 2017:1964531. PMC: 5327783. DOI: 10.1155/2017/1964531. View

Silva L, Paciello M, Aviz Teixeira W, Rivas A, Agular R, Cangussu A . Immunogenicity of HLA-DR1 and HLA-A2 peptides derived from Leishmania major Gp63 in golden hamsters. Parasite Immunol. 2020; 42(12):e12780. DOI: 10.1111/pim.12780. View

Daftarian P, Stone G, Kovalski L, Kumar M, Vosoughi A, Urbieta M . A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis. J Infect Dis. 2013; 208(11):1914-22. PMC: 3814840. DOI: 10.1093/infdis/jit378. View

Pradhan S, Schwartz R, Patil A, Grabbe S, Goldust M . Treatment options for leishmaniasis. Clin Exp Dermatol. 2021; 47(3):516-521. DOI: 10.1111/ced.14919. View

Srivastava S, Shankar P, Mishra J, Singh S . Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasit Vectors. 2016; 9(1):277. PMC: 4866332. DOI: 10.1186/s13071-016-1553-y. View

Lakhal-Naouar I, Slike B, Aronson N, Marovich M . The Immunology of a Healing Response in Cutaneous Leishmaniasis Treated with Localized Heat or Systemic Antimonial Therapy. PLoS Negl Trop Dis. 2015; 9(10):e0004178. PMC: 4618688. DOI: 10.1371/journal.pntd.0004178. View

Zhang W, Matlashewski G . CRISPR-Cas9-Mediated Genome Editing in Leishmania donovani. mBio. 2015; 6(4):e00861. PMC: 4513079. DOI: 10.1128/mBio.00861-15. View

Martins B, Barbosa Y, Andrade C, Pereira L, Simao G, de Oliveira C . Development of an Electrochemical Immunosensor for Specific Detection of Visceral Leishmaniasis Using Gold-Modified Screen-Printed Carbon Electrodes. Biosensors (Basel). 2020; 10(8). PMC: 7460044. DOI: 10.3390/bios10080081. View

10.

Taheri T, Seyed N, Mizbani A, Rafati S . Leishmania-based expression systems. Appl Microbiol Biotechnol. 2016; 100(17):7377-85. DOI: 10.1007/s00253-016-7712-4. View

11.

Soni B, Singh S . COVID-19 co-infection mathematical model as guided through signaling structural framework. Comput Struct Biotechnol J. 2021; 19:1672-1683. PMC: 7997053. DOI: 10.1016/j.csbj.2021.03.028. View

12.

Fu P . Grand Challenges in Synthetic Biology to be Accomplished. Front Bioeng Biotechnol. 2014; 1:2. PMC: 4090911. DOI: 10.3389/fbioe.2013.00002. View

13.

Torres-Guerrero E, Quintanilla-Cedillo M, Ruiz-Esmenjaud J, Arenas R . Leishmaniasis: a review. F1000Res. 2017; 6:750. PMC: 5464238. DOI: 10.12688/f1000research.11120.1. View

14.

Bejugam P, Singh S . Engineering riboswitch in L. major: From prediction to conceptualization. Int J Biol Macromol. 2018; 115:98-105. DOI: 10.1016/j.ijbiomac.2018.04.031. View

15.

Scheller J, Engelowski E, Moll J, Floss D . Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics. Trends Immunol. 2019; 40(3):258-272. DOI: 10.1016/j.it.2019.01.001. View

16.

Singh N, Kumar M, Singh R . Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med. 2012; 5(6):485-97. DOI: 10.1016/S1995-7645(12)60084-4. View

17.

Zhang W, Lypaczewski P, Matlashewski G . Application of CRISPR/Cas9-Mediated Genome Editing in Leishmania. Methods Mol Biol. 2020; 2116:199-224. DOI: 10.1007/978-1-0716-0294-2_14. View

18.

Kima P, Soong L . Interferon gamma in leishmaniasis. Front Immunol. 2013; 4:156. PMC: 3685816. DOI: 10.3389/fimmu.2013.00156. View

19.

Moafi M, Rezvan H, Sherkat R, Taleban R . Vaccines Entered in Clinical Trials: A Review of Literature. Int J Prev Med. 2019; 10:95. PMC: 6592111. DOI: 10.4103/ijpvm.IJPVM_116_18. View

20.

Alpizar-Sosa E, Ithnin N, Wei W, Pountain A, Weidt S, Donachie A . Amphotericin B resistance in Leishmania mexicana: Alterations to sterol metabolism and oxidative stress response. PLoS Negl Trop Dis. 2022; 16(9):e0010779. PMC: 9581426. DOI: 10.1371/journal.pntd.0010779. View